Similar Counterregulatory Hormone Responses to Hypoglycemia with Basal Insulin Peglispro (BIL) vs. Insulin Glargine (GL) in Type 1 Diabetes

被引：0
|
作者：
Heise, Tim
Kapitza, Christoph
Nosek, Leszek
Lam, Eric Chen Quin
Choi, Siak Leng
Garhyan, Parag
Jacober, Scott J.
Porksen, Niels
Prince, Melvin J.
Linnebjerg, Helle
机构：
来源：
DIABETES | 2015年 / 64卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
993-P
引用
下载
收藏
页码：A252 / A253
页数：2
相关论文
共 50 条
  • [41] EXPLORING THE WEIGHT-NEUTRAL EFFECTS OF INSULIN DETEMIR VS. INSULIN GLARGINE IN TYPE 1 DIABETES
    Mitchell, S.
    Burge, M. R.
    JOURNAL OF INVESTIGATIVE MEDICINE, 2009, 57 (01) : 242 - 242
  • [42] Comparing efficiency of insulin glargine vs. NPH insulin in patients with type 2 diabetes
    Kodela, B.
    Petrovic, J.
    Velickovic-Radovanovic, R.
    Lilic, R.
    Radenkovic, S.
    Dedovic, I
    VALUE IN HEALTH, 2007, 10 (06) : A254 - A254
  • [43] Similar HbA1c Reduction and Hypoglycemia with Variable Time (VT) and Fixed Time (FT) Dosing of Basal Insulin Peglispro (BIL) in Type 1 Diabetes (T1D): IMAGINE 7
    Garg, Satish K.
    Selam, Jean-Louis
    Bhargava, Anuj
    Schloot, Nanette C.
    Luo, Junxiang
    Zhang, Qianyi
    Jacobson, Jennie G.
    Hoogwerf, Byron J.
    DIABETES, 2015, 64 : A260 - A260
  • [44] Glycemic Variability with Dulaglutide vs. Basal Insulin Glargine
    Jodar, Esteban
    Romera, Irene
    Wang, Qianqian
    Caveda, Elena
    Emilio Garcia, Luis
    DIABETES, 2020, 69
  • [45] Effects of oral aminoacids on counterregulatory responses to insulin-induced hypoglycemia in type 1 diabetes mellitus
    Fanelli, CG
    Rossetti, P
    Porcellati, F
    Marzotti, S
    Bolli, GB
    DIABETOLOGIA, 2005, 48 : A293 - A293
  • [46] Incidence of severe nocturnal hypoglycemia in patients with type 1 diabetes treated with insulin lispro or regular human insulin in addition to basal insulin glargine
    Brunetti, P.
    Muggeo, M.
    Cattin, L.
    Arcangeli, A.
    Pozzilli, P.
    Provenzano, V.
    Francesconi, A.
    Calatola, P.
    Santeusanio, F.
    NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES, 2010, 20 (07) : 519 - 526
  • [47] Hypoglycemia Risk Related to Double Dose Is Markedly Reduced with Basal Insulin Peglispro Versus Insulin Glargine in Patients with Type 2 Diabetes Mellitus in a Randomized Trial: IMAGINE 8
    Harris, Cynthia
    Forst, Thomas
    Heise, Tim
    Plum-Moerschel, Leona
    Watkins, Elaine
    Zhang, Qianyi
    Fan, Ludi
    Garhyan, Parag
    Porksen, Niels
    DIABETES TECHNOLOGY & THERAPEUTICS, 2017, 19 (08) : 463 - 470
  • [48] Basal insulin peglispro increases lipid oxidation, metabolic flexibility, thermogenesis and ketone bodies compared to insulin glargine in subjects with type 1 diabetes mellitus
    Porksen, Niels K.
    Linnebjerg, Helle
    Lam, Eric Chen Quin
    Garhyan, Parag
    Pachori, Alok
    Pratley, Richard E.
    Smith, Steven R.
    DIABETES OBESITY & METABOLISM, 2018, 20 (05): : 1193 - 1201
  • [49] Cardiovascular Events in Type 2 Diabetes: Insulin Degludec vs. Glargine
    Lichert, Frank
    DIABETOLOGIE UND STOFFWECHSEL, 2017, 12 (06) : 433 - 433
  • [50] Lower Rate of Hypoglycemia with IDegLira vs. Insulin Glargine Regardless of Dosing Time or Hypoglycemia Definition in Patients with Type 2 Diabetes
    Norwood, Paul
    Chen, Roger C.
    Jaeckel, Elmar
    Lingvay, Ildiko
    Jarlov, Henrik
    Lehmann, Lucine
    Heller, Simon
    DIABETES, 2016, 65 : A105 - A106
12345